🇺🇸 FDA
Patent

US 12365688

Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors

granted A61PA61P35/00

Quick answer

US patent 12365688 (Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors) held by Revolution Medicines, Inc. expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Revolution Medicines, Inc.
Grant date
Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61P, A61P35/00